nach oben

Clinical and Translational Oncology

Erschienen in:

01.08.2014 | Research Article

Dendritic cells transfected with hepatocellular carcinoma (HCC) total RNA induce specific immune responses against HCC in vitro and in vivo

verfasst von: B. H. Xie, J. Y. Yang, H. P. Li, B. Zhang, W. Chen, B. Zhou, B. G. Peng, L. J. Liang, Q. He

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Immunotherapy is an effective method for preventing metastasis and recurrence of carcinoma. Hepatocellular carcinoma (HCC) is a common malignancy with a high rate of recurrence, and has not successfully been introduced to immunotherapy.

Methods

Peripheral blood mononuclear cells were isolated from whole blood of HCC patients and stimulated to transform into dendritic cells (DCs). These DCs were then transfected with RNA extracted from HepG-2 hepatoma cells to induce expression of specific antigens.

Results

The transfected DCs stimulated T lymphocytes to produce cytotoxic T lymphocytes, which specifically attacked HepG-2 cells. Injection of T lymphocytes from HCC patients and transfected DCs into severe combined immunodeficiency mice limited the growth of HepG-2 tumors.

Conclusion

A specific immune response against hepatoma can be generated in vivo by administering DCs transfected with RNA from a specific tumor. This method may have therapeutic application in humans to reduce recurrence of HCC.

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.PubMedCrossRef

Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol. 1996;26:659–68.PubMedCrossRef

Nouri-Shirazi M, Banchereau J, Fay J, Palucka K. Dendritic cell based tumor vaccines. Immunol Lett. 2000;74:5–10.PubMedCrossRef

Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755–66.PubMed

Halliday GM, Le S. Transforming growth factor-beta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. Int Immunol. 2001;13:1147–54.PubMedCrossRef

Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23:263–72.PubMedCrossRef

Cao H, Verge V, Baron C, Martinache C, Leon A, Scholl S, et al. In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother Stem Cell Res. 2000;9:183–94.PubMedCrossRef

Garderet L, Cao H, Salamero J, Vergé V, Tisserand E, Scholl S, et al. In vitro production of dendritic cells from human blood monocytes for therapeutic use. J Hematother Stem Cell Res. 2001;10:553–67.PubMedCrossRef

Zheng Z, Takahashi M, Narita M, Toba K, Liu A, Furukawa T, et al. Generation of dendritic cells from adherent cells of cord blood by culture with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha. J Hematother Stem Cell Res. 2000;9:453–64.PubMedCrossRef

10.

Ramadan G, Schmidt RE, Schubert J. In vitro generation of human CD86+ dendritic cells from CD34 + haematopoietic progenitors by PMA and in serum-free medium. Clin Exp Immunol. 2001;125:237–44.PubMedCentralPubMedCrossRef

11.

Hagihara M, Li C, Gansuvd B, Munkhbat B, Inoue H, Shimakura Y, et al. Extensive and long-term ex vivo production of dendritic cells from CD34 positive umbilical cord blood or bone marrow cells by novel culture system using mouse stroma. J Immunol Methods. 2001;253:45–55.PubMedCrossRef

12.

Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest. 2000;106:1065–9.PubMedCentralPubMedCrossRef

13.

Saenz-Badillos J, Amin SP, Granstein RD. RNA as a tumor vaccine: a review of the literature. Exp Dermatol. 2001;10:143–54.PubMedCrossRef

14.

Kariko K, Kuo A, Barnathan ES, Langer DJ. Phosphate-enhanced transfection of cationic lipid-complexed mRNA and plasmid DNA. Biochim Biophys Acta. 1998;1369:320–34.PubMedCrossRef

15.

Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184:465–72.PubMedCrossRef

16.

Zhang W, He L, Yuan Z, Xie Z, Wang J, Hamada H, et al. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum Gene Ther. 1999;10:1151–61.PubMedCrossRef

17.

Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol. 2000;165:5713–9.PubMedCrossRef

18.

Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998;16:364–9.PubMedCrossRef

19.

Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer. 1999;82:121–4.PubMedCrossRef

20.

Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg. 2002;235:540–9.PubMedCentralPubMedCrossRef

21.

Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med. 2000;6:1011–7.PubMedCrossRef

22.

Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 2000;60:1028–34.PubMed

23.

Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 2001;61:3388–93.PubMed

24.

Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol. 2001;166:2953–60.PubMedCrossRef

25.

Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol. 2000;164:5508–14.PubMedCrossRef

26.

Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003;63:2127–33.PubMed

27.

Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One. 2010. doi:10.1371/journal.pone.0011144.PubMedCentralPubMed

Titel: Dendritic cells transfected with hepatocellular carcinoma (HCC) total RNA induce specific immune responses against HCC in vitro and in vivo
verfasst von: B. H. Xie
J. Y. Yang
H. P. Li
B. Zhang
W. Chen
B. Zhou
B. G. Peng
L. J. Liang
Q. He
Publikationsdatum: 01.08.2014
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 8/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1145-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Dendritic cells transfected with hepatocellular carcinoma (HCC) total RNA induce specific immune responses against HCC in vitro and in vivo

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle

Neuropilin-1 is overexpressed in osteosarcoma and contributes to tumor progression and poor prognosis

Double-strand breaks on F98 glioma rat cells induced by minibeam and broad-beam synchrotron radiation therapy

Cancer incidence and mortality projections up to 2020 in Catalonia by means of Bayesian models

Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study

CHD1L is a novel independent prognostic factor for gastric cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie